Conference
Advertisement
Advertisement
Trending on Urology Times
1
NDV-01 produces robust 9-month results in high-risk NMIBC
2
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
3
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
4
New agents, biomarkers shape recent advances in bladder cancer
5
